31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
Andreas Lundqvist(Karolinska Institutet), James Geib(Idera Pharmaceuticals (United States)), Cynthia A. Sirard(Leeds Teaching Hospitals NHS Trust), Margaret K. Callahan(Cornell University), Michael A. Postow(Memorial Sloan Kettering Cancer Center), Eliot Sachsenmeier(University of Rochester), Phillip Wong(Memorial Sloan Kettering Cancer Center), Yumeng Mao(Karolinska Institutet), Jonathan J. Havel(Acorda Therapeutics (United States)), Jingjing Qi(Institute of Hematology & Blood Diseases Hospital), Vincent van Hoef(Stockholm University), Archana Thakur(University of Virginia Cancer Center), Yanyun Li(Memorial Sloan Kettering Cancer Center), Rolf Kiessling(Unknown), Ravi Murthy(The University of Texas MD Anderson Cancer Center), Marc Uemura(The University of Texas MD Anderson Cancer Center), John-William Sidhom(Cornell University), Shannon Murray, Lawrence G. Lum(University of Virginia), Jeffrey S. Weber(NYU Langone Health), Henry Koon(Case Western Reserve University), Erik Wennerberg(Institute of Cancer Research), Cara Haymaker(The University of Texas MD Anderson Cancer Center), Abhinav Deol(Wayne State University), Jedd D. Wolchok(Cornell University), Laia Masvidal Sanz(Karolinska Institutet), Jonathan P. Schneck, Vamsidhar Velcheti(Cleveland Clinic), David Woods(Moffitt Cancer Center), Anders Berglund(Moffitt Cancer Center), Roberta Zappasodi(Cornell University), Anthony F. Shields(Wayne State University), Julie Brevard(Idera Pharmaceuticals (United States)), Ola Larsson(Science for Life Laboratory), Rupal Ramakrishnan(Moffitt Cancer Center), Kristina Witt(Karolinska Institutet), Catherine Bessell(Johns Hopkins University), Timothy A. Chan(Cleveland Clinic), Walter Newman(Ensemble Therapeutics (United States)), Gregory Dyson(The Barbara Ann Karmanos Cancer Institute), Shuo Liang(Karolinska Institutet), Xiaonan Zhang(Beijing Luhe Hospital Affiliated to Capital Medical University), Catherine Monaghan(Idera Pharmaceuticals (United States)), Julie Lorent(Karolinska Institutet), S. Swann(GlaxoSmithKline (United States)), Marihella James(The University of Texas MD Anderson Cancer Center), Minsig Choi(Stony Brook University Hospital), Taha Merghoub(Cornell University), Daqing Wang(Idera Pharmaceuticals (United States)), Andressa L. Sodré(NYU Langone Health)
Cited by 11
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k